ライフサイエンスコーパス: BCG

1 BCG challenge dose affects sensitivity of this model.

2 BCG mycobacterial load was quantified by solid culture a

3 BCG strain did not significantly affect BCG recovery.

4 BCG vaccination at birth may decrease hospitalization du

5 BCG vaccination prevents disseminated tuberculosis in ch

6 BCG vaccination prior to influenza vaccination results i

7 BCG vaccine may reduce overall mortality by increasing r

8 BCG was well tolerated, and reactogenicity was similar b

9 BCG-derived DNA was detected in the cytosol of rBCG-infe

10 BCG-induced pleural infection was uncontrolled and progr

11 tis; minor allele frequency was 0.215 in 130 BCG osteitis cases and 0.298 in 99 controls (p = 0.034).

12 A meta-analysis of 3 BCG trials showed that early BCG-Denmark reduced mortali

13 We also conducted a meta-analysis of the 3 BCG-Denmark trials.

14 ollow-up was 41 years (IQR 32-49) for 83 421 BCG-unvaccinated and 44 years (41-46) for 297 905 vaccin

15 Among 15 911 BCG-vaccinated children, only 52% had a scar.

16 l, especially among children who developed a BCG scar.

17 countries, where intradermally administered BCG has inefficient effectiveness against pulmonary tube

18 , a model in which parenterally administered BCG vaccine does not protect against tuberculosis.

19 anasally but not subcutaneously administered BCG confers robust protection against pulmonary tubercul

20 BCG strain did not significantly affect BCG recovery.

21 ermore, mice that received clofazimine after BCG vaccination exhibited significantly enhanced resista

22 ng efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radi

23 rs2275913 was associated with osteitis after BCG vaccination.

24 Two weeks after BCG challenge, skin biopsy of the challenge site was per

25 echanistic insight may be exploited to allow BCG to realize its potential for unobtrusive monitoring

26 Among BCG-vaccinated children in a setting with low scar preva

27 a scar; we tested the hypothesis that among BCG-vaccinated children, a vaccination scar was associat

28 to combined culture-negative sputum DNA and BCG DNA.

29 te an association between Hb/iron levels and BCG growth in vitro, which may in part explain differenc

30 A shorter interval between MTBVAC prime and BCG boost resulted in improved efficacy in lungs, compar

31 's mandatory mass tuberculosis screening and BCG vaccination programme between 1962 and 1975.

32 of IL-6 promotes mycobacterial survival and BCG-induced lipid accumulation by a similar, but probabl

33 We obtained TST and BCG information and linked it to the National Tuberculos

34 of screening and those with unknown TST and BCG status.

35 IL-23/IL-17-dominated inflammation and anti-BCG Th1 immune responses.

36 here exposure to both compounds reduced anti-BCG levels more than exposure to either compound alone.

37 cteria is common and almost all children are BCG-vaccinated.

38 All patients with healthcare-associated BCG infection in the Barcelona tuberculosis (TB) program

39 ion of 3 patients with healthcare-associated BCG infection who had never received intravesical BCG ad

40 Patients with healthcare-associated BCG infection who had not received intravesical BCG inst

41 y volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized

42 licensed vaccines, including live attenuated BCG vaccine.

43 ncreasingly convenient ballistocardiography (BCG) instruments over the years.

44 im) and CD3(-)CD56(hi) NK cells at baseline, BCG revaccination boosted these responses, which remaine

45 rected HSCs into Ifngammar1(-/-) mice before BCG infection prevented manifestations of severe BCG dis

46 confounders, we found no association between BCG vaccination and asthma.

47 Long and short intervals between BCG prime and MTBVAC boost resulted in improved efficacy

48 ii) demonstration of proportionality between BCG cell concentration and magnetoresistive voltage sign

49 plotype (GTA) differed significantly between BCG osteitis cases and controls (0.296 vs. 0.184, p = 0.

50 However, optimal timing to boost BCG-immunity using subunit vaccines remains unclear in c

51 Revaccination transiently boosted BCG-specific Th1 cytokine-expressing CD4, CD8, and gamma

52 rmeabilization and depolarization in M bovis BCG.

53 riched with iron were infected with M. bovis BCG expressing green fluorescent protein.

54 s in lungs of immunocompetent mice, M. bovis BCG is cleared, and clearance is T cell dependent.

55 minished inflammation and growth of M. bovis BCG via enhanced reactive oxygen species production, imm

56 th of M. smegmatis and slow-growing M. bovis BCG.

57 estricting the growth of Mycobacterium bovis BCG and M. tuberculosis.

58 g regions throughout the Mycobacterium bovis BCG genome, were identified using ChIP-seq.

59 ver, a similar screen in Mycobacterium bovis BCG identified that phthiocerol dimycocerosate biosynthe

60 2 level in a conditional Mycobacterium bovis BCG mutant enhanced killing by ADEP unlike in other bact

61 ns (Mycobacterium avium, Mycobacterium bovis BCG or Mtb), were exposed to encapsulated isoniazid-PLGA

62 phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2.

63 Mycobacterium bovis BCG responded to each stage of hypoxia and aerobic resus

64 Attenuation of Mycobacterium bovis BCG strain is related to the loss of the RD1-encoded ESX

65 from mycobacteria, using Mycobacterium bovis BCG to illustrate the method.

66 ry immunity conferred by Mycobacterium bovis BCG vaccination was affected in mice with chronic enteri

67 the partially effective Mycobacterium bovis BCG vaccine.

68 culosis, live attenuated Mycobacterium bovis BCG, has variable efficacy, but development of an effect

69 ced profiles of potency (Mycobacterium bovis BCG, M tuberculosis H37Rv), selective activity, solubili

70 ng in the Mtb surrogate, Mycobacterium bovis BCG, reveals significant changes in AMP and G6P levels d

71 d, catheter-related infections with M. bovis-BCG in patients with indwelling catheters.

72 y patients with infection caused by M. bovis-BCG were studied.

73 searching for infections caused by M. bovis-BCG.

74 ttributes of lymphocyte responses boosted by BCG revaccination.

75 account the IFN-gamma production induced by BCG (IFNgamma-ESAT6BCG).

76 gamma production shared with that induced by BCG (LOD score, 3.72; P = 1.8 x 10(-5)).

77 uration profiles similar to those induced by BCG but also stronger IL-12p70 production.

78 BCG-reactive memory NK cells were induced by BCG vaccination in infants, whereas in vitro IFN-gamma e

79 gression models were fit to examine chemical-BCG associations among approximately 500 mother-infant p

80 t-assistance from Momordica cochinchinensis (BCG), one conventionally extracted from another natural

81 We combined BCG with the vaccine MTBVAC to evaluate whether the effi

82 Comparing BCG + OPV0 vs BCG only, the HR was 0.83 (95% confidence

83 In conclusion, BCG-induced pleurisy was uncontrolled in the absence of

84 kine production, and significant cell death, BCG induced a robust adult-like maturation profile of ne

85 icient infants are responsible for decreased BCG-specific T-cell responses.

86 y G/G genotype was associated with decreased BCG-specific IL-2(+) CD4(+) T-cell frequency and prolife

87 LLIP deficiency is associated with decreased BCG-specific T-cell responses and increased susceptibili

88 uses a magnetoresistive biosensor to detect BCG bacteria for tuberculosis diagnosis.

89 inflammation and succumbed from disseminated BCG infection.

90 ess efficiently and less effectively than do BCG-infected cells, in vivo and in vitro, despite higher

91 standard-dose BCG TICE (group B), high-dose BCG SSI (group C), and high-dose BCG TICE (group D).

92 We have selected high-dose BCG SSI to take forward in future challenge studies.

93 , high-dose BCG SSI (group C), and high-dose BCG TICE (group D).

94 ssigned to receive intradermal standard-dose BCG SSI (group A), standard-dose BCG TICE (group B), hig

95 andard-dose BCG SSI (group A), standard-dose BCG TICE (group B), high-dose BCG SSI (group C), and hig

96 t could deliver live attenuated freeze-dried BCG powder into the epidermis in a painless, lesion-free

97 During BCG infection, activation of Ag85B-specific CD4 T cells

98 azimine selectively expands Tcm cells during BCG vaccination.

99 o have beneficial nonspecific effects; early BCG vaccination of low-birth-weight (LBW) newborns reduc

100 ial in LBW infants in Guinea-Bissau of early BCG vs the usual postponed BCG, a subgroup was bled 4 we

101 randomized trials in Guinea-Bissau of early BCG-Denmark (Statens Serum Institut) given to low-weight

102 important that all LW infants receive early BCG in areas with high neonatal mortality rates.

103 a-analysis of 3 BCG trials showed that early BCG-Denmark reduced mortality by 38% (MRR, 0.62; 95% CI,

104 opeptide-specific T cells dominate the early BCG-induced T cell response was corroborated in restimul

105 08-2013, we randomized LW neonates to "early BCG-Denmark" (intervention group; n = 2083) or "control"

106 cted the present trial to test whether early BCG-Denmark reduces neonatal mortality by 45%.

107 the Expanded Programme of Immunisation (eg, BCG, measles, diphtheria-tetanus-pertussis, and three do

108 SULTS: Vaccination of mice with encapsulated BCG promoted a more potent immune response relative to v

109 ite high frequencies of IFN-gamma-expressing BCG-reactive CD3(+)CD56(+) NKT-like cells and CD3(-)CD56

110 uerin (BCG) has failed, the type of failure (BCG unresponsive, refractory, relapsing, or intolerant)

111 rial of vaccination with AERAS-402 following BCG.

112 sociation and positive catheter cultures for BCG in patients in whom mycobacterial cultures were perf

113 in skin test (TST) negative and eligible for BCG vaccination as part of the last round of Norway's ma

114 19 (95% CI -683 to -155; p=0.0034) fewer for BCG to -313 (95% CI-446 to -179; p<0.0001) fewer for pen

115 within the first 2 days of life, the HR for BCG + OPV0 vs BCG only was 0.58 (95% CI, .38-.90).

116 underpinned by the association observed for BCG.

117 evidence of an association was seen only for BCG (summary OR 0.73 [95% CI 0.50-1.08]).

118 IP may provide a novel adjuvant strategy for BCG vaccination.

119 cies of these SNPs differ between the former BCG osteitis patients and Finnish population controls.

120 tions and deletions (indels) across fourteen BCG strains.

121 of the Abell 2597 Brightest Cluster Galaxy (BCG), a nearby (redshift z = 0.0821) giant elliptical ga

122 (TB) infection and bacillus Calmette Guerin (BCG) vaccination.

123 ion of heat-killed bacillus Calmette-Guerin (BCG) and subsequent activation using an intradermal inje

124 llenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycobacterium tuberculosis cha

125 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licensed vaccine for tuberculo

126 patients for whom bacillus Calmette-Guerin (BCG) has failed, the type of failure (BCG unresponsive,

127 TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the MVA85A efficacy trial.

128 revaccination with bacillus Calmette-Guerin (BCG) in healthy, tuberculin skin test-positive (>/=15-mm

129 Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

130 Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

131 Bacillus Calmette-Guerin (BCG) osteitis was more common in Finland than elsewhere

132 losis and M. bovis bacillus Calmette-Guerin (BCG) Pasteur in vivo and in vitro.

133 ycobacterium bovis bacillus Calmette-Guerin (BCG) pleural infection in a murine model.

134 Bacillus Calmette-Guerin (BCG) seems to have beneficial nonspecific effects; early

135 ther refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse.

136 ssociation between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma in a birth cohort

137 mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the estimates derived from p

138 Bacille Calmette-Guerin (BCG) vaccination has been suggested to have nonspecific

139 ave suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of allergic disease

140 imary or secondary bacillus Calmette-Guerin (BCG) vaccination were assessed for Ab responses to AM vi

141 ext of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T cell responses to mycoba

142 Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorly understood.

143 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the prevention of tuberc

144 studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV),

145 ycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was lost in the absence

146 tillation with the bacillus Calmette-Guerin (BCG) vaccine.

147 Bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, is wi

148 sed on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related

149 susceptibility and bacillus Calmette-Guerin (BCG)-induced immunity are mostly unknown.

150 ycobacterium bovis Bacillus Calmette-Guerin (BCG).

151 ycobacterium bovis bacillus Calmette-Guerin (BCG).

152 mulation with live bacillus Calmette-Guerin (BCG; LOD score, 3.81; P = 1.40 x 10(-5)).

153 Healthy BCG-naive adults were assigned to receive intradermal st

154 el-arm, phase II study , 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical r

155 er vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC.

156 In BCG-vaccinated subjects, HI antibody responses against t

157 There was no difference in BCG-specific T-cell proliferation between the study arms

158 differences in hospitalization rates (HR) in BCG-vaccinated children (Basque Country, where neonatal

159 A single-dose immunization in BCG-primed adults with an adenovirus-based tuberculosis

160 profiling revealed a metabolic remodeling in BCG strains that may be reflected by altered immunogenic

161 the adhesin Apa-specific T-cell responses in BCG-primed mice and investigated its BCG-booster potenti

162 o sepsis not attributable to tuberculosis in BCG-vaccinated children under 1 year of age was also sig

163 n Immunity and Health (1974-1994), including BCG vaccination status, perinatal and sociodemographic c

164 hlorophenyl)ethylene] reduces 6-month infant BCG vaccine response.

165 Among 467 infants, BCG significantly increased the in vitro cytokine respon

166 In infants, BCG-specific T cells secreting IFN-gamma associate with

167 For instance, BCG-specific IgG levels were 37% lower for infants with

168 nfection who had never received intravesical BCG administration, an epidemiologic study was performed

169 infection who had not received intravesical BCG instillation were selected and the source of infecti

170 maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy.

171 nses in BCG-primed mice and investigated its BCG-booster potential.

172 Findings are consistent with long-lasting BCG protection, but waning of VE with time.

173 gamma production after stimulation with live BCG (Bacillus Calmette-Guerin), and a second locus on ch

174 vanted antigen 85B (Ag85B)/peptide 25-loaded BCG-mimicking nanoparticle formulation was evaluated in

175 uberculosis or BCG were transferred to mice, BCG-infected cells activated proliferation of more Ag85B

176 earance of latent bacilli with IPT modulates BCG immunogenicity following revaccination.

177 were strongly associated with lower 6-month BCG-specific antibody levels.

178 r chemical analyses and to determine 6-month BCG-specific immunoglobulin (Ig) G and IgA levels.

179 ellular response increased following mucosal BCG-prime-Apa-subunit-boost strategy compared to Apa-sub

180 aked 32-52 weeks after parenteral or mucosal BCG-priming but waned significantly by 78 weeks.

181 yrus infection localized to the gut can mute BCG-specific CD4(+) T cell priming in both the spleen an

182 ion rates of scar-positive and scar-negative BCG-vaccinated children during 6 months of follow-up in

183 Neonatal BCG had no effect on the development of RW before 13 mon

184 The effect of neonatal BCG vaccination differed significantly between children

185 ted children (Basque Country, where neonatal BCG is part of the immunization schedule and has a 100%

186 ad presented with BCG osteitis after newborn BCG vaccination.

187 83) or "control" (local policy for LW and no BCG-Denmark; n = 2089) at discharge from the maternity w

188 h new-borns were randomised 1:1 to BCG or no BCG.

189 and has a 100% coverage) as compared to non-BCG-vaccinated children (from the rest of Spain, where B

190 Intravesical administration of BCG has been associated with systemic infection.

191 Early administration of BCG-Denmark in LW infants is associated with major reduc

192 Early administration of BCG-Denmark was associated with a nonsignificant reducti

193 ive longitudinal study, we took advantage of BCG instillations, which increase local immune infiltrat

194 In vivo analysis of BCG-infected mice revealed that moderate iron supplement

195 In comparative studies, boosting of BCG-immunized mice with rLmIII/a30 induced the strongest

196 etic variation across a global collection of BCG strains.

197 ed the influence of detergent in cultures of BCG and M. tuberculosis strains on the outcome of vaccin

198 sults demonstrate that pulmonary delivery of BCG can overcome the lack of protection observed when BC

199 pared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse

200 lenged intradermally with a standard dose of BCG.

201 tudy highlights the surprising durability of BCG-boosted memory NKT-like and NK cells expressing anti

202 usted appropriately for the marked effect of BCG-attributable induration in the very young.

203 chanisms behind these nonspecific effects of BCG are not fully understood, but a shift from a TH2 to

204 nation strategy to improve on the effects of BCG in vaccinated people living in tuberculosis-endemic

205 ssess the heterologous protective effects of BCG vaccination against respiratory infection (RI) and s

206 Nonspecific effects of BCG vaccination related to enhanced function of myeloid

207 rather than boosting the waning efficacy of BCG, a vaccination schedule involving a combination of t

208 tle skin irritation, vaccination efficacy of BCG-MNAs was comparable to that of intradermal immunizat

209 of a new and robust phylogenic genealogy of BCG strains.

210 rpuscular haemoglobin and in vitro growth of BCG in whole blood from healthy UK human volunteers.

211 d reduced uptake and intracellular growth of BCG.

212 round time from patient to identification of BCG, detection of pyrazinamide resistance, and phylogene

213 The immunogenicity of BCG vaccination in HIV-exposed, uninfected infants is no

214 We therefore assessed the immunogenicity of BCG vaccine in HIV-exposed infants who received BCG at b

215 activation using an intradermal injection of BCG in complete Freund adjuvant.

216 eks after challenge and used as a measure of BCG growth and functional antimycobacterial immunity.

217 responses compared to a boost at the peak of BCG-response.

218 it-Apa-boost during the contraction-phase of BCG-response had a greater effect on the magnitude and f

219 potently expressed IL-13 in the presence of BCG or tumor cells.

220 tive results associated with the presence of BCG scar, male sex, and ages of 60 years and older, and

221 There was significantly greater recovery of BCG from the high-dose challenge groups, compared with s

222 eotide polymorphisms (SNPs) with the risk of BCG osteitis after newborn vaccination.

223 Most immunological studies of BCG or Mycobacterium tuberculosis strains grow bacteria

224 resulted in protection equivalent to that of BCG given alone.

225 ated immunity is longer lasting than that of BCG when given as a single dose.

226 Viability of BCG vaccine packaged in the caves and the mechanical str

227 f detergent in growth media and a capsule on BCG were associated with differences in the outcome of v

228 f prevaccination and postvaccination sera on BCG phagocytosis and intracellular survival were assesse

229 on (P < .01), and sera were able to opsonize BCG and M. tuberculosis grown in both the absence and th

230 ection status, bacterial drug resistance, or BCG vaccination.

231 ing equivalent numbers of M. tuberculosis or BCG were transferred to mice, BCG-infected cells activat

232 coexpression patterns of M. tuberculosis- or BCG-specific responses.

233 llenge in which previously BCG-vaccinated or BCG-naive adults in the United Kingdom were challenged i

234 However, parenteral BCG-prime-Apa-subunit-boost by a homologous route was th

235 R5(-/-) mice survived and controlled pleural BCG infection as wild-type control mice.

236 a-Bissau of early BCG vs the usual postponed BCG, a subgroup was bled 4 weeks after randomization.

237 mycobacterial challenge in which previously BCG-vaccinated or BCG-naive adults in the United Kingdom

238 boost strategy compared to Apa-subunit-prime-BCG-boost approach.

239 re common than expected in centers providing BCG therapy for bladder cancer without adequate precauti

240 ed infants were randomly assigned to receive BCG vaccination at birth (the early vaccination arm) or

241 vaccine in HIV-exposed infants who received BCG at birth or at 8 weeks of age.

242 rtion of fully immunised children (receiving BCG, three doses of polio vaccine, three doses of pentav

243 Any remaining BCG was quantified in a skin biopsy specimen obtained 2

244 ssion of proteins across five representative BCG strains of the four tandem duplication (DU) groups.

245 d until 8 weeks of age and results in robust BCG-specific T-cell responses at 14 weeks of age.

246 infection prevented manifestations of severe BCG disease and maintained lung and spleen organ integri

247 this to cultured Mycobacterium bovis strain BCG DNA and to combined culture-negative sputum DNA and

248 Such BCG-reactive memory NK cells were induced by BCG vaccina

249 hat promise greater safety and efficacy than BCG against tuberculosis.

250 Previous studies have found that BCG vaccination has nonspecific beneficial effects on ch

251 We hypothesized that BCG at birth would reduce the cumulative incidence of RW

252 We hypothesized that BCG vaccination could also enhance immune responses to i

253 Studies have suggested that BCG vaccination can have nonspecific effects, reducing g

254 Single-arm designs may be relevant for the BCG-unresponsive population.

255 Within 12 months, 73 children in the BCG + OPV group and 87 children in the BCG-only group di

256 months, 211 (10.0%) of 2100 children in the BCG group and 195 (9.4%) of 2071 children in the control

257 agnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control

258 n the BCG + OPV group and 87 children in the BCG-only group died, all from infectious diseases.

259 Little is known about how long the BCG vaccine protects against tuberculosis.

260 g approach for enhancing the efficacy of the BCG vaccine in humans.

261 ormulated a simple mathematical model of the BCG waveform.

262 e principal mechanism for the genesis of the BCG waves is blood pressure gradients in the ascending a

263 We showed that the model could predict the BCG waves as well as physiologic timings and amplitudes

264 4184 included mothers were randomized 1:1 to BCG (SSI strain 1331) or to a no-intervention control gr

265 ys of birth new-borns were randomised 1:1 to BCG or no BCG.

266 that this patient dichotomy existed prior to BCG treatment.

267 mal-birth-weight neonates were randomized to BCG only (intervention group) or OPV0 with BCG (usual pr

268 mammalian host, in particular with regard to BCG vaccination strategies.

269 macrophages from huTNF KI mice responded to BCG and lipopolysaccharide similarly to wild-type macrop

270 D56(+) NKT-like, and NK cells in response to BCG were measured using whole blood intracellular cytoki

271 erlooked contributors to poorer responses to BCG vaccine.

272 l infection with Mycobacterium tuberculosis, BCG and MTBVAC delivered via various prime-boost combina

273 A typical BCG measurement shows several waves, most notably the "I

274 same room in which other patients underwent BCG instillations for bladder cancer without required bi

275 relative to vaccination with unencapsulated BCG, including higher polysaccharide-specific capsule an

276 nd than elsewhere at the time when universal BCG vaccinations were given to Finnish newborns.

277 vitro IFN-gamma expression by NK cells upon BCG stimulation was dependent on IL-12 and IL-18.

278 rst 2 days of life, the HR for BCG + OPV0 vs BCG only was 0.58 (95% CI, .38-.90).

279 Comparing BCG + OPV0 vs BCG only, the HR was 0.83 (95% confidence interval [CI],

280 Two Apa-boosters markedly improved waning BCG-immunity and significantly reduced Mycobacterium tub

281 In total, 35,612 (46.5%) individuals were BCG vaccinated, and 5,870 (7.7%) had asthma.

282 inhibition were significantly enhanced when BCG was opsonized with postvaccination sera (P < .01), a

283 vercome the lack of protection observed when BCG is given parenterally, suggesting that respiratory t

284 zation of prime-boost regimens in mice where BCG drives persistent immune-activation and suggest that

285 ated children (from the rest of Spain, where BCG is not used).

286 In a setting in which BCG alone was highly immunoprotective, boosting of mice

287 asal portion of each microneedle, into which BCG powder could be packaged directly.

288 , H. polygyrus-infected mice challenged with BCG had a higher mycobacterial load in the liver compare

289 B peptide 25 formulation was comparable with BCG in inducing Ag85B-specific CD4(+) T-cell numbers.

290 in improved efficacy in lungs, compared with BCG given alone.

291 in improved efficacy in lungs, compared with BCG given alone.

292 al analyses, and infants were immunized with BCG.

293 studied, rs4711998 associated nominally with BCG osteitis; minor allele frequency was 0.215 in 130 BC

294 o BCG only (intervention group) or OPV0 with BCG (usual practice).

295 determined in 131 adults had presented with BCG osteitis after newborn BCG vaccination.

296 gous booster vaccines in animals primed with BCG.

297 d 72 participants who were revaccinated with BCG after IPT (n = 33) or without prior IPT (n = 39).

298 is vaccination, including revaccination with BCG, might benefit Mtb-uninfected HCWs, but most HCWs in

299 disposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-

300 Vaccination with BCG-MNA caused no overt skin irritation, in marked contr

301 ned the association of TOLLIP variation with BCG-induced T-cell responses and susceptibility to laten